According to filings with the U.S. Securities and Exchange Commission, Alixia is raising up to $3,465,450.00 in new funding. Sources indicate that as part of senior management Co-Chief Executive Officer, Helen Chen played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Alixia Derived from the intersections of cancer, aging, and immunity, our therapeutic portfolio consists of programs at various stages of preclinical development addressing multiple age-related diseases. We integrate biology, biophysics, computational chemistry & clinical input to drive new therapeutic innovation. Our lead compounds disrupt the metabolic and inflammatory triggers in both cancer and quasi-cancerous cells in the microenvironment. By impacting multiple cell types, we are enabling effective, lasting cancer treatment.

To learn more about Alixia, visit http://www.alixia.com/
Alixia Linkedin Page: https://www.linkedin.com/company/alixia-therapeutics/

Contact:
Helen Chen, Co-Chief Executive Officer
858-922-9965
https://www.linkedin.com/in/helen-y-chen-7951641/

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.